The Korean journal of internal medicine

  • 제28권4호
  • /
  • Pages.449-455
  • /
  • 2013
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer

  • Lee, Kyoung Ju (Division of Respiratory and Allergy, Department of Internal Medicine, Daejin Medical Center) ;
  • Lee, Eun Joo (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center) ;
  • Hur, Gyu Young (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center) ;
  • Lee, Sang Yeub (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center) ;
  • Kim, Je Hyeong (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center) ;
  • Shin, Chol (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center) ;
  • Shim, Jae Jeong (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center) ;
  • In, Kwang Ho (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center) ;
  • Kang, Kyung Ho (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center) ;
  • Yoo, Se Hwa (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center) ;
  • Lee, Sung Yong (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center)
  • 발행 : 2013.07.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: Chemotherapy combined with radiation therapy is the standard treatment for limited stage small cell lung cancer (LS-SCLC). Although numerous studies indicate that the overall duration of chemoradiotherapy is the most relevant predictor of outcome, the optimal chemotherapy and radiation schedule for LS-SCLC remains controversial. Therefore we analyzed the time from the start of any treatment until the end of radiotherapy (SER) in patients with LS-SCLC. Methods: We retrospectively analyzed 29 patients diagnosed histologically with LS-SCLC and divided them into two groups: a short SER group (< 60 days) and a long SER (> 60 days) group. Patients were treated with irinotecan-based chemotherapy and thoracic radiotherapy. Results: Sixteen patients were in the short SER group and 13 patients were in the long SER group. Short SER significantly prolonged survival rate (p = 0.03) compared with that of long SER. However, no significant differences in side effects were observed. Conclusions: Short SER should be considered to improve the outcome of concurrent chemoradiotherapy for LS-SCLC.

키워드

참고문헌

  1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544. https://doi.org/10.1200/JCO.2005.04.4859
  2. Stupp R, Monnerat C, Turrisi AT 3rd, Perry MC, Leyvraz S. Small cell lung cancer: state of the art and future perspectives. Lung Cancer 2004;45:105-117. https://doi.org/10.1016/j.lungcan.2003.12.006
  3. De Ruysscher D, Vansteenkiste J. Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects. Radiother Oncol 2000;55:1-9.
  4. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-271. https://doi.org/10.1056/NEJM199901283400403
  5. Kumar P. The role of thoracic radiotherapy in the management of limited-stage small cell lung cancer: past, present, and future. Chest 1997;112(4 Suppl):259S-265S. https://doi.org/10.1378/chest.112.4_Supplement.259S
  6. Anderson B, Murray D. Clinical Relevant Resistance in Cancer Chemotherapy. 1st ed. Boston: Springer, 2006.
  7. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131-146. https://doi.org/10.3109/02841868809090333
  8. Tarnawski R, Fowler J, Skladowski K, et al. How fast is repopulation of tumor cells during the treatment gap? Int J Radiat Oncol Biol Phys 2002;54:229-236.
  9. Bentzen SM, Thames HD. Clinical evidence for tumor clonogen regeneration: interpretations of the data. Radiother Oncol 1991;22:161-166. https://doi.org/10.1016/0167-8140(91)90019-D
  10. Bernier J, Bentzen SM. Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur J Cancer 2003;39:560-571. https://doi.org/10.1016/S0959-8049(02)00838-9
  11. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003;362:933-940. https://doi.org/10.1016/S0140-6736(03)14361-9
  12. Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer: what limits limited disease? Lung Cancer 2002;37:271-276. https://doi.org/10.1016/S0169-5002(02)00072-7
  13. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006;24:1057-1063. https://doi.org/10.1200/JCO.2005.02.9793
  14. Mazumdar M, Smith A, Schwartz LH. A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol 2004;57:358-365. https://doi.org/10.1016/j.jclinepi.2003.07.015
  15. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91. https://doi.org/10.1056/NEJMoa003034
  16. Bentzen SM. Repopulation in radiation oncology: perspectives of clinical research. Int J Radiat Biol 2003;79:581-585. https://doi.org/10.1080/09553000310001597002
  17. Budach W, Paulsen F, Welz S, et al. Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma. Br J Cancer 2002;86:470-476. https://doi.org/10.1038/sj.bjc.6600081
  18. Davis AJ, Tannock JF. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol 2000;1:86-93. https://doi.org/10.1016/S1470-2045(00)00019-X
  19. Wu L, Tannock IF. Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-f luorouracil. Cancer Res 2003;63:2134-2138.
  20. Pijls-Johannesma MC, De Ruysscher D, Lambin P, Rutten I, Vansteenkiste JF. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev 2005;(1):CD004700.
  21. Jones B. Rapid repopulation in radiotherapy: a debate on mechanism. Radiother Oncol 1992;24:124-126. https://doi.org/10.1016/0167-8140(92)90293-4
  22. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 1997;15:893-900. https://doi.org/10.1200/JCO.1997.15.3.893
  23. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054-3060. https://doi.org/10.1200/JCO.2002.12.071
  24. Bunn PA Jr, Lichter AS, Makuch RW, et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer: a prospective, randomized trial. Ann Intern Med 1987;106:655-662. https://doi.org/10.7326/0003-4819-106-5-655
  25. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-1624. https://doi.org/10.1056/NEJM199212033272302
  26. Mascaux C, Paesmans M, Berghmans T, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000;30:23-36. https://doi.org/10.1016/S0169-5002(00)00127-6
  27. Curran WJ Jr. Combined-modality therapy for limitedstage small cell lung cancer. Semin Oncol 2001;28(2 Suppl 4):14-22.
  28. Jeong HC, Lee SY, Kim JH, et al. Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer. Lung Cancer 2006;53:361-366. https://doi.org/10.1016/j.lungcan.2006.06.002
  29. Klautke G, Fahndrich S, Semrau S, Buscher C, Virchow C, Fietkau R. Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a phase I study. Lung Cancer 2006;53:183-188. https://doi.org/10.1016/j.lungcan.2006.04.012

피인용 문헌

  1. Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort vol.7, pp.14, 2013, https://doi.org/10.7150/jca.16741